Search - tctmd.com

Displaying 1 - 20 of 92

Sort: Relevancy | Date

Presentation ESC 2025

Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Presenter: Brian Bergmark

August 30, 2025

Presentation Controversies and Advances 2025

Familial Chylomicronemia Syndrome: Emerging Treatment Technologies

Presenter: Peter P. Toth

January 30, 2025

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Presentation TCT 2024

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presenter: David Kwon

October 29, 2024

Presentation ACC 2024

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Presenter: Steven E. Nissen

April 08, 2024

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

Presentation ACC 2024

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Presenter: Brian Bergmark

April 07, 2024

Presentation ACC 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presenter: Michael J. Koren

April 06, 2024

Presentation AHA 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presenter: Alexander C. Fanaroff

November 13, 2023

Presentation AHA 2023

Safety and Pharmacodynamic Effects of VERVE-101

Presenter: Andrew Bellinger

November 11, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

Presentation TCT 2023

TCT 461: Suboptimal Lipid Lowering Treatment After Complex PCI in Contemporary Practice

Presenter: Denise Peeters

October 25, 2023

Presentation TCT 2023

TCT 271: Characterizing pathophysiological patterns of coronary artery disease among Individuals with Elevated Lipoprotein(a).

Presenter: Mick Renkens

October 25, 2023

Presentation TCT 2023

TCT 249: Remnant Cholesterol as a Residual Risk in Patients with Atherosclerotic Cardiovascular Disease under Moderate-intensity Statin with Ezetimibe Combination Therapy or High-intensity Statin Monotherapy

Presenter: Jung-Hee Lee

October 25, 2023

Presentation TCT 2023

TCT 160: Comparative Effectiveness of Moderate-intensity Statin with Ezetimibe Combination Therapy Versus High-intensity Statin Monotherapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study

Presenter: Ji-Yong Jang

October 25, 2023

TCT 50: Statin and Ezetimibe Combination Therapy Versus Statin Monotherapy for Cardiovascular Outcomes Among Patients Undergoing PCI

Presentation TCT 2023

TCT 50: Statin and Ezetimibe Combination Therapy Versus Statin Monotherapy for Cardiovascular Outcomes Among Patients Undergoing Percutaneous Coronary Intervention: A Nationwide, Retrospective, Population-based Study Using National Health Insurance Data…

Presenter: Young-Hoon Seo

October 25, 2023

Presentation TCT 2023

TCT 628: The Impact of Long-term Exposure to Air Pollution on Plaque Characteristics Assessed by Intravascular Optical Coherence Tomography

Presenter: Juhwan Lee

October 25, 2023

Presentation TCT 2023

TCT 555: NIRS-Detected Lipid-Rich Plaques are Highly Responsive to Novel Escalated LDL-C Reduction Therapy

Presenter: Karlis Trusinskis

October 25, 2023

Advertisement

Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Familial Chylomicronemia Syndrome: Emerging Treatment Technologies

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Safety and Pharmacodynamic Effects of VERVE-101

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

TCT 461: Suboptimal Lipid Lowering Treatment After Complex PCI in Contemporary Practice

TCT 271: Characterizing pathophysiological patterns of coronary artery disease among Individuals with Elevated Lipoprotein(a).

TCT 249: Remnant Cholesterol as a Residual Risk in Patients with Atherosclerotic Cardiovascular Disease under Moderate-intensity Statin with Ezetimibe Combination Therapy or High-intensity Statin Monotherapy

TCT 160: Comparative Effectiveness of Moderate-intensity Statin with Ezetimibe Combination Therapy Versus High-intensity Statin Monotherapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study

TCT 50: Statin and Ezetimibe Combination Therapy Versus Statin Monotherapy for Cardiovascular Outcomes Among Patients Undergoing Percutaneous Coronary Intervention: A Nationwide, Retrospective, Population-based Study Using National Health Insurance Data…

TCT 628: The Impact of Long-term Exposure to Air Pollution on Plaque Characteristics Assessed by Intravascular Optical Coherence Tomography

TCT 555: NIRS-Detected Lipid-Rich Plaques are Highly Responsive to Novel Escalated LDL-C Reduction Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content